Cowen Reaffirms “Buy” Rating for Natera (NTRA)
Natera (NASDAQ:NTRA)‘s stock had its “buy” rating reiterated by analysts at Cowen in a research note issued on Thursday. They presently have a $12.00 price target on the medical research company’s stock. Cowen’s price target would indicate a potential upside of 21.83% from the company’s previous close.
Several other analysts have also recently weighed in on the stock. Canaccord Genuity reiterated a “buy” rating and issued a $15.00 price target on shares of Natera in a report on Tuesday, November 14th. Zacks Investment Research cut shares of Natera from a “hold” rating to a “sell” rating in a report on Tuesday, November 14th. Robert W. Baird reiterated a “buy” rating on shares of Natera in a report on Tuesday, October 24th. Morgan Stanley reiterated an “overweight” rating and issued a $16.00 price target (up previously from $13.00) on shares of Natera in a report on Friday, October 6th. Finally, BidaskClub upgraded shares of Natera from a “sell” rating to a “hold” rating in a report on Wednesday, August 23rd. Two analysts have rated the stock with a sell rating, one has issued a hold rating and four have assigned a buy rating to the stock. Natera currently has a consensus rating of “Hold” and an average target price of $14.50.
Natera (NASDAQ:NTRA) traded up $0.17 during trading hours on Thursday, reaching $9.85. 101,900 shares of the company traded hands, compared to its average volume of 191,513. Natera has a twelve month low of $7.35 and a twelve month high of $14.76. The company has a current ratio of 1.85, a quick ratio of 1.75 and a debt-to-equity ratio of 2.43.
Natera (NASDAQ:NTRA) last released its quarterly earnings results on Wednesday, November 8th. The medical research company reported ($0.51) earnings per share for the quarter, missing the consensus estimate of ($0.47) by ($0.04). The company had revenue of $56.66 million during the quarter, compared to the consensus estimate of $55.31 million. Natera had a negative net margin of 62.34% and a negative return on equity of 197.09%. The business’s revenue was up 5.1% on a year-over-year basis. During the same quarter last year, the firm earned ($0.50) EPS. analysts predict that Natera will post -2.15 earnings per share for the current fiscal year.
Several hedge funds have recently made changes to their positions in NTRA. Virtu KCG Holdings LLC bought a new stake in shares of Natera during the 2nd quarter valued at $126,000. Los Angeles Capital Management & Equity Research Inc. bought a new stake in shares of Natera during the 2nd quarter valued at $151,000. Goldman Sachs Group Inc. boosted its holdings in shares of Natera by 45.3% during the 1st quarter. Goldman Sachs Group Inc. now owns 17,386 shares of the medical research company’s stock valued at $154,000 after buying an additional 5,417 shares in the last quarter. Voya Investment Management LLC boosted its holdings in shares of Natera by 17.8% during the 2nd quarter. Voya Investment Management LLC now owns 14,663 shares of the medical research company’s stock valued at $159,000 after buying an additional 2,212 shares in the last quarter. Finally, Russell Investments Group Ltd. bought a new stake in shares of Natera during the 3rd quarter valued at $171,000. Hedge funds and other institutional investors own 66.06% of the company’s stock.
ILLEGAL ACTIVITY WARNING: “Cowen Reaffirms “Buy” Rating for Natera (NTRA)” was originally reported by Daily Political and is the property of of Daily Political. If you are reading this piece on another domain, it was illegally stolen and republished in violation of US and international copyright legislation. The original version of this piece can be accessed at https://www.dailypolitical.com/2017/12/21/cowen-reaffirms-buy-rating-for-natera-ntra.html.
Natera Company Profile
Receive News & Ratings for Natera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natera and related companies with MarketBeat.com's FREE daily email newsletter.